Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia

[1]  M. Krem,et al.  MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling , 2016, Oncotarget.

[2]  J. Hasford,et al.  Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV , 2016, Leukemia.

[3]  Yiguo Hu,et al.  Survival regulation of leukemia stem cells , 2016, Cellular and Molecular Life Sciences.

[4]  J. Sakamoto,et al.  Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. , 2015, The Lancet. Haematology.

[5]  Richard A. Moore,et al.  Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal , 2015, Proceedings of the National Academy of Sciences.

[6]  Y. Rojanasakul,et al.  AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis , 2015, Oncotarget.

[7]  M. Zöller.  CD44, Hyaluronan, the Hematopoietic Stem Cell, and Leukemia-Initiating Cells , 2015, Front. Immunol..

[8]  Susan Rhodes,et al.  JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. , 2014, Blood.

[9]  R. V. van Etten,et al.  IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. , 2014, Blood.

[10]  Hua Xu,et al.  CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells , 2013, Cancer Cell International.

[11]  Hua Xu,et al.  CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells , 2013, Cancer Cell International.

[12]  J. Melo,et al.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. , 2013, Blood.

[13]  M. Daidone,et al.  AF1q: A Novel Mediator of Basal and 4-HPR-Induced Apoptosis in Ovarian Cancer Cells , 2012, PloS one.

[14]  A. Hamilton,et al.  Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. , 2012, Blood.

[15]  T. Hughes,et al.  Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. , 2012, Critical reviews in oncogenesis.

[16]  M. Ringnér,et al.  CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers , 2011, BMC Cancer.

[17]  I. Bernstein,et al.  AF1q/MLLT11 regulates the emergence of human prothymocytes through cooperative interaction with the Notch signaling pathway. , 2011, Blood.

[18]  A. Tan,et al.  MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML , 2011, British journal of haematology.

[19]  Chonghui Cheng,et al.  CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. , 2011, The Journal of clinical investigation.

[20]  H. Kantarjian,et al.  Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[22]  S. Karlsson,et al.  High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event , 2010, Leukemia.

[23]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[24]  S. Kong,et al.  AF1q enhancement of γ irradiation-induced apoptosis by up-regulation of BAD expression via NF-κB in human squamous carcinoma A431 cells , 2010 .

[25]  S. Kong,et al.  AF1q enhancement of gamma irradiation-induced apoptosis by up-regulation of BAD expression via NF-kappaB in human squamous carcinoma A431 cells. , 2010, Oncology reports.

[26]  T. Holyoake,et al.  The chronic myeloid leukemia stem cell. , 2009, Clinical lymphoma & myeloma.

[27]  W. Tse,et al.  Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics , 2009, American journal of hematology.

[28]  F. E. Bertrand,et al.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy , 2009, Leukemia.

[29]  S. Kong,et al.  Oncogene AF1q enhances doxorubicin-induced apoptosis through BAD-mediated mitochondrial apoptotic pathway , 2008, Molecular Cancer Therapeutics.

[30]  W. Jin,et al.  Identification of the functional role of AF1Q in the progression of breast cancer , 2008, Breast Cancer Research and Treatment.

[31]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[32]  Jiong Wu,et al.  Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. , 2006, European journal of cancer.

[33]  R. A. Etten,et al.  Requirement for CD44 in homing and engraftment of BCR-ABL–expressing leukemic stem cells , 2006, Nature Medicine.

[34]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[35]  Pascal Reynier,et al.  Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[36]  R. Ren,et al.  Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.

[37]  J. Radich,et al.  Increased AF1q gene expression in high‐risk myelodysplastic syndrome , 2005, British journal of haematology.

[38]  J. Radich,et al.  Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. , 2004, Blood.

[39]  J. Radich,et al.  Elevated expression of the AF 1 q gene , an MLL fusion partner , is an independent adverse prognostic factor in pediatric acute myeloid leukemia , 2004 .

[40]  J. Melo,et al.  Chronic myeloid leukemia--advances in biology and new approaches to treatment. , 2003, The New England journal of medicine.

[41]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[42]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[43]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[44]  M. Zöller,et al.  Expression of CD44 variant isoforms in peripheral blood leukocytes in malignant lymphoma and leukemia: inverse correlation between expression and tumor progression. , 1996, Leukemia research.

[45]  A. Cohen,et al.  A novel gene, AF1q, fused to MLL in t(1;11) (q21;q23), is specifically expressed in leukemic and immature hematopoietic cells. , 1995, Blood.